Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA China Country Head Chris Hickey On FDA's Mission In China: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

U.S.FDA established offices in China in 2008 to improve oversight of products exported to the U.S., and to establish stronger working relationships with China's State FDA. The mission of the office initially was to implement two agreements signed with China in December 2007 to enhance regulatory cooperation in the areas of food, drugs, medical devices and animal feed (PharmAsia News, Dec. 17, 2007). PharmAsia News' China and Australia bureaus spoke recently to FDA China Country Director Christopher Hickey about the mission of the China office and progress being made in China. This is part one of a two-part interview; please look for part two in an upcoming issue of PharmAsia News.
Advertisement

Related Content

China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
China Releases First Guideline On Clinical Trial Ethical Reviews In Effort To Improve Standards
U.S. FDA China Country Head Chris Hickey On FDA's Mission In China: An Interview With PharmAsia News (Part 2 of 2)
Counterfeit Drugs Produced In China Still Threaten Chinese, U.S., Global Consumers
FDA Issues Warning Letters To Two Chinese Producers Of Adulterated Heparin: Could Prosecution Lie Ahead?
U.S. FDA Set To Strengthen Inspections Of Chinese Drugmakers, Search For Adulterants In Aftermath Of Heparin Deaths – CDER Official
U.S. FDA, PDA Kick Off First Conference On Quality Systems For China’s Manufacturers, Suppliers
Import Safety Agreement Further Entwines FDA/China Regulatory Process
Import Safety Agreement Further Entwines FDA/China Regulatory Process
Advertisement
UsernamePublicRestriction

Register

SC075801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel